Fluid balance management with loop diuretics in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: A case series

• Published in: Brain hemorrhages 2024-04, Vol.5 (2), p.74-78
• Main Authors: Akamatsu, Yosuke, Chida, Kohei, Miyoshi, Kenya, Kojima, Daigo, Nomura, Jun-Ichi, Setta, Kengo, Chiba, Takayuki, Koji, Takahiro, Fujiwara, Shunrou, Kashimura, Hiroshi, Kubo, Yoshitaka, Ogasawara, Kuniaki
• Format: Article
• Language: English
• Subjects: Aneurysmal subarachnoid hemorrhage; Clazosentan; Symptomatic vasospasm
• ISSN: 2589-238X; 2589-238X
• DOI: 10.1016/j.hest.2023.10.003

Pulmonary edema is a common complication in patients receiving clazonsentan. Here, we report our experience in managing fluid balance with loop diuretics in patients with aneurysmal subarachnoid hemorrhage (aSAH) treated with clazosentan. Patients with aSAH who received prophylactic agents for vasospasm after aneurysm obliteration between June 2021 and April 2023 were enrolled. Fluid balance parameters and asymptomatic and symptomatic vasospasm and pulmonary edema incidence were compared in three periods: 1st period (fasudil therapy), 2nd period (clazosentan therapy alone), and 3rd period (clazosentan with loop diuretic therapy). Fluid intake and urine volume during the 2nd and 3rd periods were considerably lesser than those during the 1st period. Asymptomatic vasospasm incidence was considerably lesser in the 3rd period than that in the 1st and 2nd periods. However, the incidences of symptomatic vasospasm and rescue endovascular treatment were comparable among the three groups. Although the clinical outcomes at the last follow-up were comparable among the three groups, pulmonary edema incidence was markedly higher during the 2nd period than that in the 1st and 3rd periods. Thus, proper management of fluid balance with clazosentan and diuretics would help in effective clazosentan therapy for vasospasm prophylaxis.